how do glp-1 agonists work Glucagon-like peptide-1 receptor: mechanisms and advances in therapy What is GLP-1 & Does

Furthermore,...

While most of the recent fanfare has been related to their ro...

GLP-1 levels correlate with disease severity

Obesity is the fifth leading risk factor for global deaths with numbers continuing to increase worldwide

Ahead of the Trump administrations planned expansion of Medicare coverage for GLP-1s to treat obesity through temporary models and the availability of Medicares negotiated price for certain GLP-1 products beginning in 2027, this analysis examines CMSs Medicare Part D claims data from 2019 to 2024 to document the increase in the number of beneficiaries being treated with GLP-1 drugs and the growth in Medicare spending and claims for these drugs.